摘要
过敏性疾病是影响儿童健康及生活质量的常见疾病,很多患儿经过常规治疗症状仍难以控制。奥马珠单抗是一种具有高度特异性及结合性的人源化单克隆抗IgE抗体,现已被批准作为中至重度持续性哮喘及慢性自发性荨麻疹(chronic spontaneous urticaria,CSU)患者的附加治疗方式,同时也有数据证实其在其他过敏性疾病中的疗效及安全性。该文主要综述了奥马珠单抗在儿童过敏性疾病中的应用,并重点讨论了各种疾病临床实践中的疗效评价体系,同时探讨潜在生物标志物对疗效的预测与评价作用。
Allergic diseases which affect children′s health and quality of life are common diseases.Many pediatric patients′symptoms are uncontroled after routine treatments.Omalizumab,a highly specific and binding humanized monoclonal anti-IgE antibody,has been approved as an additional treatment for moderate to severe persistent asthma and chronic spontaneous urticaria now.At the same time,there are also data confirming its efficacy and safety in other allergic diseases.This review mainly summarizes the application of omalizumab in children with allergic diseases,and focuses on the evaluation system of clinical efficacy in various diseases.Meanwhile,it discusses how the potential biomarkers predict and evaluate clinical reactions.
作者
王肖玲(综述)
王雪艳
刘长山(审校)
Wang Xiaoling;Wang Xueyan;Liu Changshan(Department of Pediatrics,the Second Hospital of Tianjin Medical University,Tianjin 300211,China)
出处
《国际儿科学杂志》
2021年第10期676-681,共6页
International Journal of Pediatrics
基金
天津市卫生行业重点攻关项目(16KGl16)。
